Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma

Table 1 Results of serum GPDA-F in patients and healthy subjects

	GPDA-F (+)		GPDA-F (-)
	n	%	n	%
Healthy subjects	0	0	80	100.0
PHC	87a	85.3	15	14.7
Liver cirrhosis	5	11.1	40	88.9
Chronic hepatitis	8	33.3	16	66.7
Benign liver space-	0	0	35	100.0
occupying lesions
Metastatic hepatic cancer	3	15.0	17	85.0
Extra-hepatic cancer	8	16.0	42	84.0

^aP < 0.05 vs other groups. True positive (TP) = 87; False positive (FP) = 24 (5 + 8 + 0 + 3 + 8); False negative (FN) = 15; True negative (TN) = 150 (40 + 16 + 35 + 17 + 42); Sensitivity = TP/(TP + FN) × 100%; Specificity = TN/(TN + FP) × 100%; Diagnostic accuracy = (TP + TN)/(TP + TN + FP + FN) × 100%.

Table 2 Relationship between AFP and GPDA-F in sera of cases with PHC

AFP (ng/mL)	n	GPDA-F (+)
< 50	28	21 (75.0%)
-400	12	11 (91.6%)
> 400	62	55 (88.7%)

Table 3 Diagnostic value of both AFP and GPDA-F in PHC

	Sensitivity (%)	Specificity (%)	Accuracy (%)
AFP alone	72.5	95.2	85.0
GPDA-F alone	85.3	87.1	86.3
AFP and GPDA-F	91.2	84.7	88.5

Table 4 Relationship between GPDA-F and ALT in different liver diseases

	ALT (-x± s, u/L)
	PHC	Hepatic cirrhosis	Chronic hepatitis
Negative GPDA-F	31.0 ± 9.6	31.6 ± 3.6a	67.3 ± 13.2a
Positive GPDA-F	50.1 ± 10.2	67.6 ± 31.6	159.8 ± 46.6

^aP < 0.05 vs positive GPDA-F group.